

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:


1. (Currently Amended) A compound ~~Compounds~~ of formula (I)

cyclo [NX₁-R₁-CO-NX₂-R₂-CO-NX₃-R₃-CO-NX₄-R₄-CO-NX₅-R₅-CO]

where: R₁ is selected from:

CH(CH₂)₃NHC(NH)NH₂; C[CH_nF_m](CH₂)₃NHC(NH)NH₂

R₂ is the group CH₂; CH₂-CH₂;




R₃ is selected from CHCH₂COOH; C[CH_nF_m]CH₂-COOH;

R₄ is selected from CH-CH₂-Ph; C[CH_nF_m] CH₂-Ph; CH-CH₂-(4-OH)Ph;

CH-CH₂-(4-OMe)Ph; CH-CH₂-(4-F)Ph; CH-CH(OH)-Ph; C(CH₃)₂; CH-

C(CH₃)₃;

CH-CH₂-COOH;



R₅ is selected from CH-CH₂-Ph; C[CH_nF_m]CH₂-Ph; CH-CH(CH₃)₂;

C[CH_nF_m]CH

(CH₃)₂; CH-C(CH₃)₃;

or, the group NX₄-R₄-CO-NX₅-R₅-CO is 3-aminomethyl-benzoyl N + M = 3

X₁-X₅, which may be the same or different, are H, (CH₂)_n-CH₃;



$(CH_2)_n-CHF_2$, $(CH_2)_n-CH_2F$, $(CH_2)_n-CF_3$ where $n = 0-3$;

with the proviso that there is at least one α -fluoroalkylated amino acid present in the formula (I) compound;

where each NX-R-CO amino acid can have an absolute type R or type S configuration; their individual enantiomers, diastereoisomers, the related mixtures, the pharmaceutically acceptable salts.

2. (Currently Amended) Compound according to claim 1, selected from the group consisting of :

- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-Tfm-Phe);
- c (Arg-Gly-Asp-D-Phe-(*R*, *S*)-Dfm-Phe);
- c (Arg-Gly-Asp-(*R* or *S*)-Tfm-Phe-Asp-D-Phe-Val);
- c (Arg-Gly-Asp-(*R* or *S*)-Tfm-Phe-Val) SEQ ID NO:1;
- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-Tfm-Val) and
- c (Arg-Gly-Asp-D-Phe-(*R* or *S*)-N-Me-Tfm-Phe.

3.(Currently Amended) A method of inhibiting receptors belonging to the family of the integrins belonging to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ system in a human, said method

comprising administering a compound according to claim 1 to said mammal in a manner whereby said receptors are inhibited ~~Use of the compounds according to claim 1 as medicaments.~~

4. (Currently Amended) A method of preparing a medicament comprising admixing a compound of ~~Use of the compounds according to claim 1 with a pharmaceutically acceptable vehicle or excipient for the preparation of medicaments that inhibit the receptors belonging to the family of the integrins belonging to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ system.~~

5. (Currently Amended) The method of claim 3 wherein angiogenic activity of said human is inhibited ~~Use according to claim 4, where said medicaments have antiangiogenic activity.~~

6. (Currently Amended) The method of claim 3 wherein metastatic activity of said human is inhibited ~~Use according to claim 5, where said medicaments have antimetastatic activity.~~

7. (Currently Amended) The method of claim 3 wherein said human has ~~Use according to claim 5, where said medicaments are useful for the treatment of a disease selected from the group consisting of retinopathy, acute kidney failure, and osteoporosis.~~

8. (Previously Presented) Pharmaceutical compositions containing at least one compound according to claim 1 as an active ingredient in a mixture with pharmaceutically acceptable vehicles and/or excipients.

Claim 9. (Canceled)

10. (Currently Amended) A compound of claim 1 further comprising a label~~Use according to claim 9, where said compound is labelled.~~

11. (Currently Amended) A method of detecting the location of a tumor in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said tumor is detected~~Use according to claim 9, where said diagnostic agent is used for the detection and location of tumour masses.~~

12. (Currently Amended) The method of claim 11 wherein said tumor is a small tumor mass~~Use according to claim 11, where said tumour masses are small.~~

13. (Currently Amended) A method of detecting the location of an arterial occlusion in a human comprising administering to said human a compound of claim 10 and detecting said label in said human in a manner whereby the location of said arterial occlusion is detected~~Use according to claim 9, where said diagnostic agent is used for detecting and locating arterial occlusion events.~~

14. (Currently Amended) The method of claim 13 wherein said arterial occlusion is the result of ~~Use according to claim 13, where said event is a stroke or myocardial~~ infarct.

Claim 15. (Canceled)